Publications by authors named "G Schiller"
Acute myeloid leukaemia (AML) arising from a myeloproliferative neoplasm (MPN) is more aggressive and less responsive to therapies compared to de novo AML. Olutasidenib, an oral small-molecule inhibitor of mutated IDH1 (mIDH1), showed encouraging and durable responses in a phase 1/2 study of adults with post-MPN mIDH1 AML. Patients received olutasidenib 150 mg BID monotherapy or in combination with azacitidine.
View Article and Find Full Text PDFIn this multicenter phase Ib trial, we investigated the combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory acute myeloid leukemia (AML). Cohort A received CPX-351 plus a single dose of GO, while cohort B received two doses of GO. Thirteen participants received investigational treatment.
View Article and Find Full Text PDFArticle Synopsis
- * The study, called KOMET-001, was conducted in multiple countries and involved dose-escalation and validation phases, with patients in specific molecular subtypes receiving varying doses of ziftomenib over 28-day cycles.
- * Results indicated that 83 patients were treated with ziftomenib from September 2019 to August 2022, and the findings are crucial for determining the drug's safety and effectiveness for future phases of clinical testing.
Article Synopsis
- The study focused on patients with relapsed or refractory multiple myeloma (RRMM) who previously received lenalidomide, examining the effectiveness of a treatment combination involving pomalidomide, daratumumab, and dexamethasone (DPd).
- During the trial, a total of 112 patients were treated, with a median overall survival (OS) of 56.7 months after 41.9 months of follow-up, showing promising results.
- The treatment was generally safe, with adverse events leading to discontinuation in a small percentage of patients, suggesting that this combination therapy could be a viable option for RRMM patients needing further treatment post-lenalidomide.
Article Synopsis
- Mucorales infections lead to high morbidity and mortality rates in immunocompromised patients, such as those receiving solid organ or hematopoietic cell transplants, despite advances in diagnosis and treatment.!* -
- A study analyzed 43 patients with Mucorales infections, finding that most developed the infection around 184 days post-transplant, with a 64% overall mortality rate; fatalities were mainly linked to Mucormycosis and common in disseminated disease.!* -
- The findings highlight a gap in effective prophylaxis and treatment strategies, indicating that improved data post-transplant can aid in managing Mucormycosis and emphasizing the need for further research on antifungal treatments.!